Dr. Matt Kaeberlein joins The Cat Health Company's advisory board

The Cat Health Company said Sept. 29, 2026, that aging researcher Dr. Matt Kaeberlein has joined its Scientific Advisory Board. The move adds a prominent companion-animal longevity scientist as the biotech advances its first cat-aging drug program and prepares for regulatory submission.

Why it matters: - Dr. Matt Kaeberlein brings nearly three decades of aging research, clinical translation and company-building experience to a biotech focused on cat longevity. - The appointment strengthens The Cat Health Company’s effort to turn aging science into treatments for companion animals and, potentially, broader human-relevant insights. - The company’s lead program, PURR-001, is already in clinical development and moving toward regulatory review.

What happened: - The Cat Health Company announced on Sept. 29, 2026, that Dr. Matt Kaeberlein joined its Scientific Advisory Board. - The San Francisco-based clinical-stage biotech develops longevity medicines for cats. - Kaeberlein is a scientist focused on mechanisms of aging shared across species and how to target them to extend healthspan and lifespan. - Kaeberlein said the early PURR-001 results in age-related muscle loss were an encouraging example of the company’s approach.

The details: - Kaeberlein has published more than 250 scientific papers. - His honors include the Robert W. Kleemeier Award from the Gerontological Society of America and the Nathan W. Shock Award from the National Institute on Aging. - Since co-founding the Dog Aging Project in 2014, Kaeberlein has co-directed research on client-owned dogs at home. - That work has combined long-term observational studies with placebo-controlled clinical trials, including trials of low-dose repurposed rapamycin. - The Cat Health Company said Kaeberlein’s work overlaps with its own in three areas: conserved mechanisms of aging, drug repurposing and faster clinical applications for companion animals and human medicine. - PURR-001, the company’s first clinical-stage program, targets age-related muscle loss. - The program reached a European manufacturing and distribution agreement less than two years after the company’s founding. - In a randomized, placebo-controlled trial, cats treated with PURR-001 showed an average 23% increase in epaxial muscle thickness. - The treated group’s result was 2.5 times higher than the placebo group. - Hematology and serum biochemistry stayed within normal limits at every timepoint. - Adverse events occurred at similar rates in both study arms. - The company is preparing the dossier for regulatory submission. - The pipeline also includes candidates for renal, neurological and cardiovascular conditions. - The Cat Health Company combines computational models, laboratory assays and clinical validation to develop therapeutics. - The company said its scientific team has published computational methods, lab findings and clinical data in peer-reviewed journals including Cell and Nature. - The company is expanding its team and actively recruiting.

Between the lines: - The board appointment signals that The Cat Health Company wants outside validation from a well-known longevity scientist as it moves from early data to regulatory work. - The company’s emphasis on companion animals reflects a growing strategy in longevity biotech: use pets as a faster clinical path for aging-related therapies. - Kaeberlein’s work in dogs and The Cat Health Company’s work in cats both point to a broader bet that aging biology can be targeted across species.

What’s next: - The Cat Health Company will continue preparing PURR-001’s regulatory submission. - The company’s broader pipeline will advance alongside efforts to expand the team. - Kaeberlein will advise the company as it pushes cat-aging therapeutics toward clinical validation and future development.

The bottom line: - The Cat Health Company is adding a prominent aging scientist just as its first cat therapy moves closer to regulatory review.